Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573

NCT02405065 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: HM95573

Sponsor

Hanmi Pharmaceutical Company Limited